Clinical trials: Demyelinating Disorder
Multiple Sclerosis, Relapsing-Remitting
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
- Trial name
- NCT01909492
- Testing
- Blood Draw, Lumbar Puncture
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis, Neuropathic Pain
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
- Trial name
- NCT01604265
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
EFFECTS OF AEROBIC AND RESISTANCE TRAINING ON IMMUNE FUNCTION IN MULTIPLE SCLEROSIS
Background: Multiple Sclerosis (MS) is a chronic immune-mediated, inflammatory, and neurodegenerative central nervous system disorder characterized by axonal damage.
- Trial name
- ABIF-MS (NCT07640100)
- Testing
- Aerobic and Progressive Resistance Exercise Program, Standard Care (in control arm)
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Seda Saka
Charcot-Marie-Tooth Neuropathy Type 1A, Hereditary Transthyretin Amyloid Neuropathy
Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients
The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F).
- Conditions
- Charcot-Marie-Tooth Neuropathy Type 1A, Hereditary Transthyretin Amyloid Neuropathy, Acquired Demyelinating Neuropathy
- Trial name
- IMAGINERV (NCT06845644)
- Testing
- Quantitative neuromuscular MRI, Neuromuscular ultrasound
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Multiple Sclerosis, Spasticity
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS)…
- Trial name
- NCT01844232
- Testing
- arbaclofen
- Where
- 35 sites in United States, Russia and 1 more
- Volunteers
- 150 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity
The study aimed to explore the link between urinary incontinence (UI) severity in patients with multiple sclerosis (PwMS), electromyography (EMG) findings, and other relevant factors.
- Trial name
- NCT07236684
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Artvin Coruh University
Clinically Isolated Syndrome, Multiple Sclerosis
Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion
This is a multicentric and prospective study for the validation of a diagnostic method in multiple sclerosis. Our hypothesis is that there is a characteristic profile of tears that can be recognized in order to help in the…
- Trial name
- POLAR (NCT02043964)
- Testing
- tears and cerebrospinal fluid sampling
- Where
- 15 sites in France
- Volunteers
- 165 people
- Sponsor
- Lille Catholic University
Multiple Sclerosis
The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis
Despite the benefits of exercise and physical activity people with Multiple Sclerosis (MS) are relatively inactive. Physical activity is important for persons with disabilities to maintain physical function.
- Trial name
- MStep (NCT01611987)
- Testing
- MStep, General guideline approach
- Where
- 5 sites in Canada
- Volunteers
- 240 people
- Sponsor
- McGill University
Multiple Sclerosis, Progressive Multiple Sclerosis
Effect of Variance on Error Correction During Coupling
This study is a case-control study, involving persons with progressive multiple sclerosis and healthy controls. The study contains 1 descriptive and 3 experimental sessions.
- Trial name
- NCT04856384
- Testing
- synchronisation abilities
- Where
- 2 sites in Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Multiple Sclerosis, Secondary Progressive
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive…
- Trial name
- INSPIRE (NCT02430532)
- Testing
- dimethyl fumarate
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- Biogen
Alzheimer Disease, Parkinson Disease
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
Ultimately a marker of microglial activation could be used for large-scale quantitative brain imaging trials in Alzheimer Disease (AD), Parkinson Disease (PD) or Multiple Sclerosis (MS), specifically to investigate the agent as…
- Conditions
- Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
- Trial name
- NCT00970333
- Testing
- [18F]-FEPPA
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Institute for Neurodegenerative Disorders
Multiple Sclerosis
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
- Trial name
- NCT04933552
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
The purpose is to see how multiple sclerosis (MS) is associated with strength and sensation using MRI, in persons with MS. The investigators will also see whether exercise can improve these symptoms for persons with MS.
- Trial name
- NCT01632293
- Testing
- progressive resistance training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- TYPIFI (NCT04832399)
- Testing
- Natalizumab
- Where
- 18 sites in Portugal
- Volunteers
- 60 people
- Sponsor
- Biogen
NMO Spectrum Disorder, Spasticity, Muscle
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD.
- Trial name
- SENS-NMO (NCT05974293)
- Testing
- Nabiximols
- Where
- United States
- Sponsor
- Michael, Levy M.D.,Ph.D.
Multiple Sclerosis
GSK239512 DDI Study
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers.
- Trial name
- NCT01802931
- Testing
- GSK239512, ketoconazole
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.
- Trial name
- NCT05298670
- Testing
- MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- German University in Cairo
Multiple Sclerosis
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting
The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting.
- Trial name
- NCT06261541
- Testing
- ABLE Exoskeleton
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- ABLE Human Motion S.L.
Multiple Sclerosis
Cognitive and Emotion Regulation Training in MS
The investigators propose to conduct a randomized feasibility study of mindfulness meditation training (MMT) relative to an active cognitive training control group and waitlist control group in improving emotional regulation in…
- Trial name
- CERT-MS (NCT02717429)
- Testing
- Mindfulness Meditation, Computerized Cognitive Training
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.